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Abstract
Aims Our aim was to summarize the available literature on the effect of short- versus long-course antibiotic therapy on 
acute cholangitis.
Methods A systematic review was performed according to the PRISMA Statement. We searched three databases for papers 
discussing the length of ABT in acute cholangitis. Long and short therapy groups were defined based on the most recent 
guideline available at the time of publication of the articles. Primary outcomes were the rate of recurrent cholangitis and 
mortality; secondary outcomes included length of hospitalization and the duration of fever after ERCP. Data were extracted 
on these outcomes and on general characteristics. A narrative synthesis was then provided based on collected data.
Results Out of 692 articles produced by our search, four met our inclusion and exclusion criteria. These contained 205 acute 
cholangitis patients, with 137 and 68 patients receiving short and long antibiotic therapy, respectively. No significant dif-
ference was observed in any of the studies on the outcomes of mortality and duration of fever after ERCP between the two 
groups. One out of four studies found the rate of recurrent cholangitis to be significantly lower in the short antibiotic therapy 
group (0.0% vs. 13.3%, p = 0.036). Length of hospitalization was only compared in the same retrospective article, where it 
was found to be significantly shorter in the short-term antibiotic therapy group (with a median of 14 vs. 17.5 days, p < 0.001).
Conclusions Our review suggests short-course antibiotic therapy is non-inferior to long-course treatment; however, several 
limitations underline the need for well-designed randomized trials.
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Abbreviations
ABT  Antibiotic treatment
ERCP  Endoscopic retrograde 
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NOS  Newcastle–Ottawa Scale
PRISMA-P  Preferred Reporting Items for Systematic 
Review and Meta-Analysis Protocols
RCT  Randomized controlled trial
Introduction
Acute cholangitis is a bacterial infection of the bile ducts 
that can be life-threatening if not diagnosed and treated in 
time [1].
The most up-to-date and widely used guidelines on the 
subject are the 2018 Tokyo Guidelines. A separate subarticle 
of these guidelines specifically deals with the topic of anti-
microbial treatment for acute cholangitis [2]. The previous 
versions of the Tokyo Guidelines were published in 2007 
and 2013 [3, 4].
According to guidelines provided by the European Soci-
ety of Gastrointestinal Endoscopy (ESGE) and the Ameri-
can Society of Gastrointestinal Endoscopy (ASGE) as well 
as the 2018 Tokyo Guidelines, the general treatment of the 
disease should involve a source control procedure along with 
antibiotic therapy [5, 6]. To control the source of infection, 
drainage of biliary tract is necessary with either endoscopic 
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or percutaneous transhepatic biliary drainage in grade II or 
III acute cholangitis [3]. Antimicrobial therapy is also rec-
ommended in all cases of acute cholangitis [2]. Mortality 
ranges between 5 and 10%, depending on comorbidities, the 
modality of treatment applied, and the severity grade of the 
disease [7].
ABT enables the usage of elective drainage procedures 
rather than urgent ones [8]. The 2018 Tokyo Guidelines pro-
vide a description of the specimen that should be obtained 
to identify the microorganisms causing the infection (bile 
cultures as the first choice), the antimicrobial agents to pre-
scribe in each severity grade of the disease, and the optimal 
route and duration of administration. The guidelines rec-
ommend 4–7 days of treatment once the source of infec-
tion is controlled, regardless of severity. If bacteremia with 
Gram-positive cocci is present, antibiotic therapy should 
be administered for at least two weeks for the prevention 
of infective endocarditis [2]. The guidelines describe these 
previous recommendations on the length of antimicrobial 
therapy as strong; however, the quality of evidence is based 
on expert opinion and thus remains low.
The importance of the duration of antibiotic therapy 
(ABT) in cholangitis does not only originate from obvious 
financial reasons, but also from the multiple harmful effects 
of the (potentially) unnecessarily long ABT as well.
The aim of this study was to systematically review the lit-
erature currently available on the length of antibiotic therapy 
in acute cholangitis to evaluate if short-course ABT is non-
inferior to long-course ABT for the treatment of the disease.
Materials and Methods
Our systematic review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) Statement [9]. The protocol was 
registered at PROSPERO on January 26, 2018, under regis-
tration number CRD42018083638.
Search
A comprehensive search was carried out by two independent 
authors using three databases (PubMed, EMBASE, and the 
Cochrane Library). The aim was to gather relevant articles 
on the topic of ABT in patients with acute cholangitis from 
inception up to November 11, 2017.
The PICO items were the following: We included stud-
ies that examined patients with acute cholangitis diagnosed 
according to the most recent guidelines available at the time 
(P), with at least one group of acute cholangitis patients that 
were treated with antibiotic therapy for a short duration. A 
short-course ABT was defined as treatment with antibiotics 
for a shorter duration than that is suggested by the available 
protocol or guideline at the publication date of the study (I). 
We imposed no restriction in terms of the etiology of chol-
angitis. We had no strict requirement for a control group as 
that criterion would have narrowed the number of articles 
included even further; when available, we considered the 
group of patients who received the traditional, long course 
of ABT as a control group. Long-course ABT was defined 
as treatment with antibiotics for the traditional length of time 
(or more) as suggested by the then available guideline (C). 
In terms of outcomes, we considered the rate of recurrent 
cholangitis and mortality as our primary outcomes and the 
length of hospitalization (LOH) and duration of fever after 
the ERCP procedure as secondary outcomes (O).
We used the following query in all three databases: 
“Cholangitis AND (Antibiotic OR Antimicrobial) AND 
(Duration OR Length OR Stop OR Cessation OR Discon-
tinuation).” For a draft of our search strategy, see Supple-
mentary File 1: Our search strategy.
We limited our search to human and English language 
studies via the appropriate filters when searching in Pub-
Med and EMBASE. The Trials filter was applied when 
searching for articles in the Cochrane Library. To expand 
the search, we performed a recursive hand search on the 
references of relevant articles.
We also searched PROSPERO, an international data-
base for systematic reviews and meta-analyses, for previ-
ously completed reviews on the subject.
Inclusion and Exclusion Criteria
We excluded the following types of publications: letters, 
comments, case reports, case studies, conference abstracts, 
editorials, and reviews.
In our review, we included both observational (cohort, 
cross-sectional cohort, and case–control) and interven-
tional (randomized and non-randomized, controlled and 
non-controlled) trials and studies. We included studies 
with both prospective data collection and retrospective 
data collection, regardless of their primary objectives. 
If there were multiple publications on the same group of 
patients, the latest was always chosen.
Screening and Selection
After the initial search, all results were imported into a refer-
ence management program (EndNote X7, Clarivate Analyt-
ics, Philadelphia, PA, USA). The software was used in the 
process of removing duplicates by searching for articles with 
overlapping publication year, author, and/or title.
After duplicates were removed, the authors screened the 
remaining articles against the pre-defined eligibility criteria 
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by title, abstract, and then full text. Two different research-
ers conducted each step simultaneously. Any disagreements 
were resolved by consensus.
Data Extraction
Numerical data were extracted by two investigators and 
manually entered on an Excel 2016 sheet (Office 365, Micro-
soft, Redmond, WA, USA). Data were collected on the first 
author, year of publication, study design, geographical loca-
tion, number of patients, and basic demographics (age and 
sex ratio) in each group. Data were extracted on the defini-
tion of the groups and the length of ABT in each. Finally, 
data were collected on the four outcomes of interest noted 
previously.
Quality Assessment and Quality of Evidence
A modified version of the Newcastle–Ottawa Scale (NOS) 
was used to assess the quality of cohort studies included 
in the analysis [10]. Supplementary File 2 shows the NOS 
Quality Assessment Form for Cohort Studies modified to 
fit the study design of the articles included. The Cochrane 
Risk of Bias Tool was used to assess the quality of the RCT 
included [11]. We used the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) meth-
odology to rate the quality of evidence as high (level A), 
moderate (level B), low (level C), or very low (level D). The 
strength of recommendations was also graded according to 
the same guidelines as strong (1) or weak (2) [12].
Results
Study Selection
Our search yielded a total of 692 articles, 101 in PubMed, 
566 in EMBASE, and 25 in the Cochrane Library. After 
removing duplicates and checking the titles and abstracts 
against the eligibility criteria, six articles were assessed by 
full text and, finally, four were deemed eligible for system-
atic review [13–16]. The reason for discarding the last two 
studies was that they did not include a separately analyzed 
subgroup of patients with short ABT [17], or the patients 
were treated with short-course ABT, but only a fraction of 
them had acute cholangitis (and no subgroup analysis was 
performed) [18]. Two out of the four eligible studies were 
prospective [14, 15] and two were retrospective [13, 16]. 
These included a total of 205 acute cholangitis patients with 
137 and 68 of them receiving short- and long-course ABT, 
respectively (Fig. 1). Collected data and the characteristics 
of the studies included are shown in Tables 1 and 2.
Rate of Recurrent Cholangitis
All of the four articles [13–16] assessed the rate of recur-
rent cholangitis during the follow-up and were included in 
the systematic review. In van Lent et al., 23.7% (n = 19) of 
all the patients (n = 80) developed recurrent cholangitis, 
with 26.8% (n = 11) in the short ABT group (ABT for three 
or fewer days), 21.1% (n = 4) in the medium-length ABT 
group (ABT for 4–5 days), and 20.0% (n = 4) in the long 
ABT group (ABT for more than five days). The p value (0.8) 
showed no statistically significant difference across groups 
[13]. In Kogure et al. and Limmathurotsakul et al., none of 
the 34 patients examined in these studies had a recurrent 
episode of cholangitis during their follow-up period [14, 
15]. In Uno et al., the recurrence rate was 4.4% (n = 4) in 91 
patients, with 0.0% (n = 0) and 13.3% (n = 4) in the short and 
long ABT groups, respectively. This difference appeared to 
be significant (p = 0.036) [16].
Mortality
All of the four articles included [13–16] assessed mortal-
ity. Van Lent et al. reported a 11.3% (n = 9) overall mortal-
ity among the patients included, with 14.6, 10.5, and 5% 
(n = 6, 2, 1) in the short, medium, and long ABT groups, 
respectively. This difference between groups did not prove 
to be significant [13]. In both Kogure et al. and Limma-
thurotsakul et al., there were no deaths registered among 
the 34 patients included in total [14, 15]. In Uno et al., two 
deaths were observed among the 91 patients (2.2%), both 
of which occurred in the long ABT group, accounting for a 
5.7% mortality in this group, with no significant difference 
between the short and long ABT groups (p = 0.179) [16].
Length of Hospital Stay
LOH was only assessed in one study. Uno et  al. [16] 
reported a 14-day median LOH (IQR: 10.0–17.0 days) for 
the short ABT group and a 17.5-day median LOH (IQR: 
16–22.5 days) in the long ABT group with a significant dif-
ference in between (p < 0.001).
Duration of Fever Following ERCP
Three out of the four articles included data on the duration of 
fever after the ERCP procedure. Van Lent et al. only reported 
a median of one day of fever (range 0–17 days) duration 
after ERCP for all patients in the study [13]. Kogure et al. 
found the median duration of fever to be two days across all 
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patients included [14]. Limmathurotsakul et al. reported the 
duration to be 1.8 h (SD 1.8) in the short ABT group and 
1.2 h (SD 0.7) in the long ABT group. The authors of this 
study found no significant difference between the two groups 
in terms of fever duration (p = 0.467) [15].
Discussion
To date, no meta-analysis or separate systematic review has 
been published on the subject of the duration of antibiotic 
therapy in acute cholangitis. We aimed to summarize the 
available literature on the topic by systematically reviewing 
articles that compare long- and short-course ABT in acute 
cholangitis.
There is evidence that prolonged ABT increases the risk 
of antibiotic resistance in microorganisms; however, there 
is no clear correlation between early cessation of antibiotic 
therapy and an increased chance of resistance [19]. A recent 
meta-analysis showed that longer ABT duration and mul-
tiple courses are associated with higher rates of resistance 
in respiratory and urinary tract infections [20]. Moreover, 
in the case of orally administered antibiotics, the risk of 
Clostridium difficile colitis is also an issue clinicians must be 
aware of. Another meta-analysis lists cephalosporins as one 
of the main causes of Clostridium difficile infections [21]. As 
stated previously, this group of antibiotics is recommended 
for the baseline therapy of acute cholangitis in all severity 
grades [2]. Furthermore, longer ABT duration is associated 
with longer hospital stay [16], thus leaving the patients at 
risk of the many, well-documented complications of pro-
longed hospitalization, such as pneumonia, venous thrombo-
embolism, and muscle loss [22, 23], which especially affect 
the elderly [23].
A recent randomized controlled trial (RCT) carried out by 
Sawyer et al. came to the conclusion that a fixed, short (four-
day) duration of antimicrobial treatment for intraabdominal 
infections might be sufficient after a successful source con-
trol procedure has been completed. In that study, however, 
patients presenting with acute cholangitis only accounted 
for a small percentage of the total population [18]. The high 
mortality rate of acute cholangitis underlines the need for 
similar studies specifically designed to assess the exact dura-
tion of antibiotic treatment in this type of infection.
Van Lent et al. [13] state that the fear of complications 
of acute cholangitis is what currently drives clinicians to 
Fig. 1  PRISMA flowchart for 
the study selection process. 
From: Moher D, Liberati 
A, Tetzlaff J, Altman DG, 
The PRISMA Group (2009) 
Preferred Reporting Items 
for Systematic Reviews and 
Meta-Analysis: The PRISMA 
Statement. PLoS Med 
6(6):e1000097. https ://doi.
org/10.1371/journ al.pmed1 
00009 7. For more information, 
visit http://www.prism a-state 
ment.org
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prescribe antibiotics for longer periods of time. However, 
their results suggest that there is no significant difference 
between short-course ABT and long-course ABT in terms 
of complications, at least in the case of complete biliary 
drainage. Without achieving biliary drainage, the risk of a 
hepatic abscess increases due to the continuously elevated 
pressure in the infected bile ducts [24]. On the other hand, 
if the intervention is successful, complications mostly occur 
shortly after the endoscopic procedure [25, 26], with the 
exception of recurrent cholangitis, which is reported to 
develop at a median time of 18 weeks after the drainage and 
can be observed in 14% of patients [27]. Observation of this 
length was only conducted in one out of the four articles 
included [13].
The total recurrence and mortality rates (23.7% and 
7.2%, respectively) were extraordinarily high in van Lent 
et al. compared to all the others [13]. This is likely a 
result of the high ratio of acute cholangitis patients with 
malignancy as an etiological factor (36 patients out of 80, 
45%). Moreover, the number of patients with the previous 
stent placement was also high in this study (50 patients 
out of 80, 62.5%), which may also have contributed to 
the high recurrence and mortality reported. Excluding 
van Lent et al., the recurrence and mortality rate varied 
between 0–4.4 and 0–2.2%, respectively.
Kogure et al. hypothesize that a fever-based antibiotic 
cessation (i.e., discontinuing the antibiotic therapy once 
the patient’s temperature falls below a certain threshold, 
such as 37 °C in their case) might be sufficient for the 
treatment of acute cholangitis, even in cases combined 
with sepsis [14].
The conclusion that antibiotic therapy can safely be 
stopped after a short duration even in sepsis may be 
explained by the fact that in the case of cholangitis, 
Table 1  Characteristics of studies included
a Mean
b Standard deviation
References Country Design Patient 
number
Male (n) Groups ABT length 
(days)
Age (years, 
mean, SD)
Follow-
up (days, 
median)
Outcomes 
measured
van Lent 
et al. [13]
Netherlands Retrospective 
case–con-
trol
41 Not specified G1: ABT for 
3 days or 
less
Less than 
3 days
Not speci-
fied, article 
states that 
groups 
are well 
matched
71 Mortality, 
recurrent 
cholan-
gitis19 G2: ABT for 
4–5 days
4–5 days 143
20 G3: ABT for 
more than 
5 days
More than 
5 days
181
Kogure et al. 
[14]
Japan Prospective 
single arm
18 12 Short ABT 
therapy 
group
3a 73 (12) 28 Mortality, 
recurrent 
cholangi-
tis, dura-
tion of 
fever after 
ERCP
Limma-
thurotsakul 
et al. [15]
Thailand Randomized 
controlled 
trial
8 5 G1: ABT 
stopped 
after 
temperature 
below 37.8 
degrees for 
72 h
5a (1.7b) 73.1 (15.9) 56 Mortality, 
recurrent 
cholangi-
tis, dura-
tion of 
fever after 
ERCP
8 5 G2: Full 
14 days of 
ABT
14a (0.0b) 66.5 (15.3) 56
Uno et al. 
[16]
Japan Retrospective 
cohort
51 35 G1: less than 
2 weeks of 
ABT
10a 76 (11.1) 56 Mortality, 
recurrent 
cholangi-
tis, length 
of hospi-
talization
40 23 G2: more 
than 
2 weeks of 
ABT
14.5a 81.7 (7.95) 56
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bacteremia occurs due to biliary obstruction [28]. Once 
the source of infection is controlled (with biliary drain-
age), bacteremia is likely to resolve, and the patient may 
not need further ABT [15].
In their retrospective cohort study, Uno et al. aimed to 
validate an ABT duration of less than 14 days for Gram-
negative bacteremia in acute cholangitis. They compared 
patients receiving less than 14 days of ABT to patients 
receiving ABT for longer. They concluded that the mortality 
did not significantly differ between each of the groups, and 
they observed fewer recurrences in the short-term antibiotic 
therapy group.
None of the articles included found any significant dif-
ference between short- and long-term antibiotic treatments 
in terms of mortality and duration of fever after the ERCP 
procedure. The rate of recurrent cholangitis was found to 
be significantly lower in the short ABT group in one article 
[16], and no significant difference was found in the other 
three. The length of hospitalization was only assessed in one 
study included, and a difference was found between the two 
groups, with significantly shorter hospitalization time in the 
short-term ABT group [16]. We hypothesize that the unu-
sually long hospital stay in both groups (median of 14 and 
17.5 days) in this study occurred because they only included 
cholangitis patients with confirmed positive blood cultures.
Quality of Evidence and Quality Assessment
Figure 2 and Table 3 show the results of the quality assess-
ment of the studies included. With regard to the RCT (by 
Limmathurotsakul et al.), the Cochrane Risk of Bias Tool 
indicated an overall poor quality, since three points (blinding 
of participants and personnel; blinding of outcome assess-
ment; and selective reporting) were evaluated as having a 
potentially high risk of bias (see Table 3).
Applying the GRADE approach to each of the outcomes 
assessed above resulted in a weak (2) recommendation and 
a very low (D) level of evidence for every outcome [12].
Limitations
During the process of conducting our systematic review, we 
came across several potential limitations that may impair the 
strength of our findings. In terms of general characteristics, 
the low number of articles (n = 4) that could be included 
in the final review and the low combined patient number 
(n = 205, with n = 137 cases and n = 68 controls) are insuf-
ficient to provide basis for strong recommendations. Moreo-
ver, only one of these studies is randomized and controlled, 
and it only involves 16 patients (n = 8 cases and n = 8 con-
trols) [15]. We also included an article without a control 
(comparison, short-course ABT) group [14], and two out 
Table 2  Data extracted on outcomes
a Days
b Hours
c Range
d Standard deviation
References Groups Patient 
number 
(n)
Mortality (n, %) Recurrent 
cholangitis 
(n, %)
Duration of fever after 
ERCP (days/hours, 
median, range/SD)
Length of hospitali-
zation (days, median, 
IQR)
van Lent et al. [13] G1: ABT for 3 days 
or less
41 6 (14.6) 11 (26.8) 1a (0–17a,c)
G2: ABT for 4–5 days 19 2 (10.5) 4 (21.1)
G3: ABT for more than 
5 days
20 1 (5.0) 4 (20.0)
Kogure et al. [14] Short ABT therapy 
group
18 0 (0) 0 (0) 2a
Limmathurotsakul et al. 
[15]
G1: ABT stopped after 
temperature below 
37.8 degrees for 72 h
8 0 (0) 0 (0) 1.8b (1.8b,d)
G2: full 14 days of 
ABT
8 0 (0) 0 (0) 1.2b (0.7b,d)
Uno et al. [16] G1: less than 2 weeks 
of ABT
51 0 (0) 0 (0) 14 (16–22.5)
G2: more than 2 weeks 
of ABT
40 2 (5.7) 4 (13.3) 17.5 (10.0–17.0)
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of the four studies utilized retrospective data collection [13, 
16].
In addition, the inclusion criteria were not the same in the 
articles. Uno et al. [16] only included cholangitis patients 
with positive blood culture, and there was a difference 
between the severities of cholangitis in the inclusion crite-
ria across the studies analyzed. Furthermore, the type and 
regimen of antibiotics, as well as the definition and tim-
ing of successful biliary drainage procedures, also varied 
greatly. The causes of acute cholangitis were not consistent 
Fig. 2  Results of the Newcas-
tle–Ottawa quality assessment 
scale for cohort studies
Table 3  Cochrane Risk of Bias Tool for RCTs, applied for Limmathurotsakul et al. [15]
Entry Judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: “The randomization codes were generated by a computer 
using a random mixing box”
Comment: Probably done
Allocation concealment (selection bias) Unclear risk Quote: “Concealed in envelops”
Comment: Insufficient details to allow definite judgement: Were the 
envelops sealed and/or sequentially numbered?
Blinding of participants and personnel (performance bias) High risk Comment: No blinding mentioned in terms of allocated interven-
tions (the group of patients), and the lack of blinding is likely to 
influence the outcomes
Blinding of outcome assessment (detection bias) (patient-
reported outcomes)
Unclear risk Quote: “The concealed randomization code was opened by an 
investigator who was blinded to the treatment results”
Comment: Probably referring to the treatment results of the biliary 
drainage and not the outcomes of the study
Blinding of outcome assessment (detection bias) (mortality) High risk Comment: No blinding mentioned in terms of outcome assessment 
(the group of patients), and the lack of blinding is likely to influ-
ence the outcomes
Incomplete outcome data addressed (attrition bias) Low risk Comment: No missing outcomes reported. Probably true, especially 
with the low patient number
Selective reporting (reporting bias) High risk Comment: An outcome listed in methods is not described in detail: 
the overall morbidity and mortality related to acute cholangitis
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across the studies. For example, Limmathurotsakul et al. 
[15] excluded all causes except for common bile duct stones; 
however, the other studies were not so restrictive in terms 
of etiology.
With regard to the methodology in the studies, the follow-
up period ranged from one to six months in the four stud-
ies included. This inconsistency may have an influence on 
outcomes, such as mortality and recurrent cholangitis rate 
during follow-up, especially when taking into consideration 
that the median time for developing recurrent cholangitis is 
18 weeks after biliary drainage [27]. The criteria or reasons 
for the cessation of antibiotic therapy were not clearly stated 
in all the studies. In Kogure et al. and Limmathurotsakul 
et al., antibiotic treatment was stopped after the patient’s 
temperature dropped below a certain threshold (37 °C and 
37.8 °C, respectively) for a period of time (24 h and 72 h, 
respectively). Neither of these studies specifies the proto-
col of the temperature measurement used, and only Kogure 
et al. [14] provide data on the method of measurement. The 
other two articles contain no information on the protocol for 
stopping antibiotic therapy. Supplementary File 3 highlights 
some of the major differences between studies that contrib-
ute to the limitations of our review.
Conclusions
According to the synthesized results and conclusions from 
the articles included in our systematic review, short-course 
ABT seems adequate for the treatment of acute cholangitis 
once biliary drainage has been achieved. However, due to 
the low number of patients included, the differences in study 
design, and the heterogeneity of the definition used for long 
and short-course treatment, the quality of evidence remains 
very low.
In view of the conclusions of our systematic review, we 
believe that a new randomized controlled study is needed on 
the duration of antibiotic treatment in acute cholangitis to 
provide high-quality evidence on the topic.
This conclusion provides a foundation for a future 
planned RCT we plan to conduct to satisfy the need for high-
quality evidence.
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